Vident Investment Advisory’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Vident Investment Advisory’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-37,304	Closed	-$2.73M	–	665
2019 Q1	$2.73M	Sell	37,304 -1,303	-3%	-$88.6K	0.15%	174
2018 Q4	$1.64M	Sell	38,607 -8,974	-19%	-$358K	0.09%	299
2018 Q3	$2.24M	Sell	47,581 -3,431	-7%	-$191K	0.09%	301
2018 Q2	$2.52M	Buy	+51,012	New	+$1.93M	0.1%	277

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vident Investment Advisory's MRTX Position: Q2 2019 in Review

Vident Investment Advisory sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2019, closing a stake of 37,304 shares — an estimated $2.73M sold.

Vident Investment Advisory first reported a position in MRTX in Q2 2018 and held it in 4 quarters. The position peaked at $2.73M in Q1 2019. 172 funds tracked by Wall St. Rank hold MRTX as of Q2 2019.

Vident Investment Advisory reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Vident Investment Advisory sold 37,304 Mirati Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $2.73M.
Vident Investment Advisory first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2018 and held it in 4 quarters.
Vident Investment Advisory's Mirati Therapeutics, Inc. Common Stock position peaked at $2.73M in Q1 2019.
172 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Vident Investment Advisory's 13F filing for Q2 2019, filed 12 Aug 2019.